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ABSTRACT
The purpose of this study was to report visual prognosis after explantation of a small-aperture corneal inlay used for the
treatment of presbyopia. This is a retrospective case series conducted at a single site in Draper, Utah, USA (Hoopes Vision).
Medical records of 176 patients who had received a small-aperture corneal inlay (KAMRA™, AcuFocus Inc., Irvine, CA, USA) were
reviewed. Patients who had undergone explantation of the device were identified. Uncorrected distance visual acuity (UDVA),
uncorrected near visual acuity (UNVA), corrected distance visual acuity (CDVA), and manifest refraction spherical equivalent
(MRSE) were measured pre-implantation, post-implantation, pre-explantation, and post-explantation of the inlay. Ten eyes from
ten patients were included in this study. The explantation rate was 5.7% over 31 months, with blurry vision as the most
common complaint. After explantation, six patients achieved pre-implantation UDVA, and six achieved pre-implantation UNVA.
Eight of nine patients who underwent final manifest refraction achieved pre-operative CDVA. All patients had residual donutshaped corneal haze in the stroma at the previous position of the inlay. All patients experienced improvement in haze with 20%
experiencing complete resolution. The degree of stromal haze was not related to the duration of implantation. Of the subset of
patients who underwent explantation of their small-aperture corneal inlay, there was persistent loss of CDVA in 10%. The
majority of patients experienced some level of residual stromal haze, which may contribute to deficits in UNVA and CDVA in few
patients. A hyperopic shift induced by the corneal inlay may contribute to the blurry vision these patients experienced; there
was a reduction of this shift post-explantation. While this device is removable, patients should expect some post-explantation
changes such as residual haze with a small subset experiencing persistent deficits in CDVA.
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INTRODUCTION
The KAMRA™ inlay (AcuFocus Inc., Irvine, CA, USA) is an
implantable ring-shaped device for the treatment of
presbyopia. It is designed for the non-dominant eye and
approved by the U.S. Food and Drug Administration (FDA)
and European Commission. The inlay is 3.8mm in diameter
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with a 1.6 mm diameter hole in the center and is made of
Polyvinylidene Fluoride with carbon black pigment. It is
implanted into a corneal pocket created by a femtosecond
laser. Using the principle of pinhole optics, it increases the
depth of focus and improves near vision without
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compromising the distance acuity [1]. Recent studies have
demonstrated both the safety and efficacy of the device
[2-4]. While the inlay is typically well tolerated, there are
cases of patients requesting removal secondary to visual
disturbances, unsatisfactory results, or other adverse
outcomes that can accompany corneal and refractive
surgeries [2-5]. In the initial FDA trial of 508 eyes, the
explantation rate was 7.1% and 8.7% at 24 and 36 months
respectively [1]. As this is a relatively new device, current
literature on the visual outcomes following explantation of
the inlay is lacking. We report on the visual outcomes of
ten patients who underwent explantation of the KAMRA™
inlay.
METHODS
This study is a retrospective case series of patients who
underwent explantation of the KAMRA™, small aperture
corneal inlay. Between May 2015 and August 2018, 176
patients received the inlay at the Eye Surg of Utah, Hoopes
Vision, United States. The medical records of patients who
underwent KAMRA implantation were reviewed to identify
all patients who had undergone explantation of this device
from May 2015 to December 2018. The device removed in
this study was the third-generation KAMRA™ corneal inlay
(ACI7000PDT). Data on Snellen uncorrected distance visual
acuity (UDVA), uncorrected near visual acuity (UNVA),
corrected distance visual acuity (CDVA), and manifest
refraction spherical equivalent (MRSE) were gathered at
four time points: pre-implantation, post-implantation, preexplantation, and post-explantation of the inlay. Approval
was obtained from the Hoopes research committee, and
informed consent was signed by each patient. All
procedures adhered to the tenets of the Declaration of
Helsinki. Data obtained from patients were expressed in
mean, frequency, and percentage.
RESULTS
Ten patients (5.7%) underwent explantation during a 31month period secondary to complaints of “blurry vision” (6
patients), nighttime glare/difficulty driving at night (3
patients), discomfort (2 patients), unsatisfactory near
vision (2 patients), and light sensitivity (1 patient). The
average amount of time from implantation to explantation
was 482 days (range 153-735); the time between
explantation and most recent follow-up examination was
190 days on average (range 8-388). All eyes that
underwent explantation had no other simultaneous
corneal refractive surgery, i.e. LASIK. The average depth of
implantation was 234 micrometers (range 205-250 µm).
One patient underwent KAMRA repositioning prior to
explantation, which did not alleviate symptoms. Fig. 1
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show the changes in anterior segment optical coherence
tomography (OCT) of stromal and epithelial maps before
and after explantation.
Uncorrected distance visual acuity outcome: After
explantation six of ten (60%) patients achieved preimplantation UDVA (Table 1; Fig. 2). The average line
change on the Snellen chart for UDVA between preimplantation and post-explantation was -0.5 (Table 1). The
median line change for UDVA was 0 (range -3 to +1).
Uncorrected near visual acuity outcome: Seven of ten
(70%) patients achieved pre-implantation UNVA (Table 1);
the average line change difference on UNVA was -0.3
(Table 1). The median line change for UNVA was 0 (range 4 to -1) (Table 1).
Corrected distance visual acuity outcome: CDVA was
retained by nine out of ten patients. One patient
remained with a two-line loss greater than three months
after explantation.
Haze: Fifty percent of patients had subjective complaint of
haze, and all patients had some degree of corneal stromal
haze on exam (Fig. 3). Two patients had complete
objective resolution of haze (at one and three months
respectively), while all other patients had residual stromal
haze (up to 1.5 years after explantation). There was no
correlation between the duration of implantation and the
amount of stromal haze after explantation.
Manifest refraction spherical equivalent: Nine patients
completed final manifest refraction, and eight of the nine
patients achieved pre-operative CDVA (Table 1). A
hyperopic shift (ranging from +0.625 to +2.0 D) was noted
in MRSE before explantation in 5 patients (50%) (Table 2).
After explantation, this hyperopic shift completely or
partially reversed in 4 of 5 patients.
DISCUSSION
The results of this study demonstrate the removability
and relative reversibility of the KAMRA corneal inlay.
After explantation, most patients can expect to trend
toward pre-implantation visual acuities. However, there
is a risk that they may not achieve baseline acuity. In
addition, patients can expect an improvement in haze
or hyperopic shift, but these changes may be persistent
after inlay removal.
The KAMRA inlay had over 20,000 implantations during
the first year of its release [6]. However, there have
been few reports on inlay explantation and subsequent
outcomes. The rate of KAMRA corneal inlay
explantation in the literature ranges from 1.5-10% [1, 4,
7, 8]. In the original FDA trial, the vast majority of
explantations were due to refractive shifts or
dissatisfaction with visual outcomes [1]. Yilmaz et al.
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reported explantation secondary to either refractive
shifts or flap complications [7]. Other studies reported
explantation most often secondary to poor acuity or
haze [4, 8, 9]. Other complaints may include “blurry
vision”, decreased night vision, night glare, starbursts,
halo, photophobia, and unsatisfactory near visual acuity
[1, 10]. Our institution had an explant rate of 5.7% over
approximately 2.5 years. In our series, 60% of patients
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who requested explantation complained of “blurry
vision.” The term blurry vision is somewhat ambiguous,
and the exact nature of what the term means to each
patient varies. Blurry vision could be due to distortions
from corneal haze, inlay induced hyperopic shift,
irregular astigmatism, or a combination of these
factors.

Figure 1: Anterior segment optical coherence tomography (OCT) imaging 3 months’ post-implant (A), pre-explantation (B), and post-explantation (C) of
KAMRA inlay. The induced donut-shaped topographic change develops with time and normalizes after explantation. (Case 8).
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Figure 2: Visual Acuity Line Changes (Line Change) for UDVA, UNVA, and CDVA.
Abbreviations: UDVA: Uncorrected Distance Visual Acuity; UNVA: Uncorrected Near Visual Acuity; CDVA: Corrected Distance Visual Acuity

Table 1: Comparison of Visual Acuity from Pre-implantation to Most Recent Exam Post-explantation. Mean Values for UDVA and CDVA are Preserved,
While There is a Slight Decrease in UNVA Post-explantation. Snellen Line Change is the Difference between Pre-implantation and Post-explantation.
Pre-implantation
Pre-explantation
Post-explantation
Snellen line change
Case
UDVA
UNVA
CDVA
UDVA
UNVA
CDVA
UDVA
UNVA
CDVA
UDVA
UNVA
CDVA
1*
20/20
20/50
20/20
20/25
20/40
20/20
20/30
20/50
20/20
-2
0
0
2*
20/30
20/32
20/20
20/200
20/40
20/20
20/40
20/25
20/20
-1
1
0
3**
20/40
20/63
20/20
20/50
20/63
20/20
20/30
20/80
20/20
1
-1
0
4*
20/15
20/50
20/20
20/25
20/50
20/25
20/25
20/50
20/20
-2
0
0
5
20/20
20/40
20/20
20/25
20/80
20/20
20/20
20/40
20/20
0
0
0
6
20/20
20/40
20/20
20/20
20/50
20/20
20/20
20/40
20/20
0
0
0
7
20/20
20/50
20/20
20/40
20/50
20/20
20/15
20/40
20/15
1
1
1
8**
20/25
20/50
20/20
20/30
20/63
20/20
20/25
20/63
20/20
0
-1
0
9**
20/25
20/40
20/20
20/40
20/50
20/20
20/20
20/100
20/20
1
-4
0
10‡
20/20
20/40
20/20
20/40
20/25
20/30
20/40
20/32
20/30
-3
1
-2
Mean
20/25
20/40
20/20
20/40
20/50
20/ 20
20/25
20/50
20 /20
-0.5
-0.3
-0.1
Abbreviations: UDVA: Uncorrected Distance Visual Acuity; UNVA: Uncorrected Near Visual Acuity; CDVA: Corrected Distance Visual Acuity
*: post-explantation loss of UDVA. **: post-explantation loss of UNVA. ‡: post-explantation loss of CDVA and UDVA

Figure 3: Corneal Haze Remaining at 1 Month (A) and 2.5 Months (B) after KAMRA Explantation in the Same Patient. The Degree of Corneal Haze
Appears to Diminish with Time. (Case 10).

The data suggests that the majority of patients can
expect to return to similar pre-implant values for UNVA
and UDVA (Table 1; Fig. 2). While most patients regained
pre-implantation CDVA, there is a risk that a patient may
never regain their pre-operative CDVA. A hyperopic shift
induced by the corneal inlay may contribute to the blurry
vision. This shift may resolve either completely or
partially after explantation. Complete resolution of
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hyperopia was seen in two of the patients with hyperopic
shift (Table 2). Persistent residual corneal haze in the
corneal stroma was common but did not result in loss of
CDVA. This haze decreased over time (Fig. 3). The exact
location of the haze (anterior or posterior) is difficult to
assess. In the future, densitometry could aid in more
specific characterization of the haze. Additionally, the
implant induces a donut-shaped change in corneal
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epithelium (Fig. 1B). Topographical changes in the
corneal epithelium appear to progress with the amount
of time the inlay is in place (Fig. 1). However, this
topographical change became more uniform after device
explantation (Fig. 1C). This observation further reinforces
the relative reversibility of the effects of the inlay.
One limitation of this study is the relatively small sample
size of patients who underwent explantation. Another
limitation was the non-uniformity in follow up times.
Despite these limitations, this study reports a wide
variety of effects seen during inlay implantation and
demonstrates trends of what patients may expect after
explantation. Future research with a larger cohort and
more consistent long-term follow up could help further
characterize visual prognosis after KAMRA removal.
Table 2: Comparison of Manifest Refraction Spherical Equivalent
(MRSE) From Pre-implantation to Post-explantation of KAMRA inlay.
Five Patients Experienced a Hyperopic Shift Post-implantation, Which
Either Completely or Partially Resolved After Explantation.
Pre-implantation Pre-explantation Post-explantation
Case
MRSE
MRSE
MRSE
1
-0.25
-0.75
-0.375
2
-0.75
-1.625
-1.125
3
-0.75
-0.75
+0.25
4†
-0.125
+0.625
-0.25
5†
-0.375
+0.625
-0.5
6
0
0
-0.375
7†
-0.375
+1.625
+0.125
8†
-0.5
+0.75
+0.375
9†
-0.75
-0.125
NA
10
-0.375
-1.25
-0.75
Mean
-0.425
-0.088
-0.292
†Patients with hyperopic shift pre-explantation. NA: Not Available.

CONCLUSION
The results of this case series demonstrate the
removability of the inlay and relative reversibility of the
effects of the KAMRA inlay. On average, patients lost a
few letters of UDVA and UNVA post-explantation.
However, two patients had two or more lines lost on
either CDVA or UNVA. In light of these findings,
consideration should be taken regarding potential longterm consequences of explantation in a patient who does
not tolerate the inlay. Patients should be aware that they
may not return to their pre-implantation visual acuity
and that some degree of residual haze post-explantation
is likely.
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